<DOC>
	<DOCNO>NCT00764322</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor learn difference DNA predict well patient respond treatment plan well treatment . PURPOSE : This clinical trial study blood sample woman breast cancer ductal carcinoma situ receive tamoxifen .</brief_summary>
	<brief_title>Studying Blood Samples From Women With Breast Cancer Ductal Carcinoma In Situ Who Are Receiving Tamoxifen</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate change endoxifen level increase tamoxifen citrate dose 20 mg 40 mg woman breast cancer ductal breast carcinoma situ intermediate-metabolizing CYP2D6 genotype . Secondary - To evaluate tolerability increase dose tamoxifen citrate 20 40 mg per day patient . - To assess feasibility obtain pharmacogenomic information patient clinical set use guide change therapy . - To examine CYP2D6 allele frequency endoxifen level among African-American woman take tamoxifen citrate . - To evaluate change plasma endoxifen level increase tamoxifen citrate dose 20 mg 40 mg daily patient poor-metabolizing genotype . - To study patient understand pharmacogenomics obstacle participation clinical trial base upon germline DNA . OUTLINE : This multicenter study . Blood sample collect baseline determine CYP2D6 genotype tamoxifen citrate metabolic status ( i.e. , poor-metabolizing [ PM ] , intermediate-metabolizing [ IM ] , extensive-metabolizing [ EM ] allele ) . Samples also analyze plasma level endoxifen N-desmethyltamoxifen endoxifen/N-desmethyltamoxifen ratio . Patients find IM PM notify increase tamoxifen citrate 40 mg/day 4 month ( absence unacceptable toxicity ) repeat endoxifen N-desmethyltamoxifen level ( ratio ) end time . All patient complete Quality Of Life ( QOL ) Menopausal Symptoms Scale ( MSS ) questionnaires baseline 4 month treatment . Toxicities assess end 4 month . Patients undergo repeat questionnaire assessment understand use pharmacogenomics clinical decision-making . Some patient also undergo 30-minute , baseline interview regard attitude experience towards participation pharmacogenomics study . Patients choose informed result genotyping contacted letter , along physician , offer genetic counseling discus significance result . After completion study therapy , patient follow 3-6 month , include toxicity assessment QOL MSS questionnaire .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive carcinoma breast ductal breast carcinoma situ Has receiving tamoxifen citrate dose 20 mg/day least 4 month either treatment invasive noninvasive carcinoma breast breast cancer recurrence prevention Expected duration tamoxifen citrate treatment least 6 month Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 02 Life expectancy ≥ 6 month ANC ≥ 1.0 x 10^9/L Platelet count ≥ 100 x 10^9/L AST ALT ≤ 2.5 time upper limit normal ( ULN ) Total bilirubin ≤ 2.5 time ULN Creatinine clearance ≥ 50 mL/min Not pregnant nursing Fertile patient must use effective contraception No active , serious infection medical psychiatric illness likely preclude study participation No psychiatric condition would preclude study compliance inform consent No history venous thromboembolism , transient ischemic attack , cerebral vascular accident No history allergic reaction tamoxifen citrate reagent PRIOR CONCURRENT THERAPY : No limitation number prior therapies No limitation prior radiotherapy More 14 day since prior concurrent investigational agent No concurrent coumadin No concurrent medication know inhibit CYP2D6 , include follow : Amiodarone Haloperidol Indinavir Ritonavir Quinidine No concurrent selective serotonin reuptake inhibitor , except follow : Venlafaxine Citalopram Concurrent participation nontreatment study allow provide interfere participation study</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>menopausal symptom</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>